Consolidated net sales for the third quarter of the fiscal year ending March 2026 were JPY 87,487 million (up 8.4% YoY), operating income was JPY 7,526 million (up 3.9% YoY), and net income attributable to owners of parent was JPY 6,342 million (up 13.2% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4534-20260330-04.pdf","jir_short_summary":"Consolidated net sales for the third quarter of the fiscal year ending March 2026 were JPY 87,487 million (up 8.4% YoY), operating income was JPY 7,526 million (up 3.9% YoY), and net income attributable to owners of parent was JPY 6,342 million (up 13.2% YoY).","jir_summary":"### Overview of Business Performance\nDuring the cumulative consolidated third quarter period of the fiscal year ending March 2026, Mochida Pharmaceutical Co., Ltd. recorded net sales of JPY 87,487 million (up 8.4% YoY), operating income of JPY 7,526 million (up 3.9% YoY), ordinary income of JPY 8,346 million (up 9.2% YoY), and net income attributable to owners of parent of JPY 6,342 million (up 13.2% YoY). The pharmaceutical-related business increased sales YoY supported by growth in new drugs, while the healthcare business also saw an 8.2% increase in net sales compared to the previous year. Research and development expenses amounted to JPY 8,984 million, focusing on enhancing the drug discovery pipeline and incorporating new modalities.\n\n### Financial Condition and Future Outlook\nTotal assets amounted to JPY 182,220 million, and net assets were JPY 137,431 million, both increasing compared to the previous consolidated fiscal year-end. Meanwhile, the equity ratio was 75.4%, down from 81.6% YoY. The number of issued shares was 36,390,000 shares, and treasury shares totaled 940,091 shares, nearly unchanged from the previous year. The annual dividend forecast remains unchanged at JPY 80.00 per share. The full-year earnings guidance projects net sales of JPY 115,500 million (up 9.8% YoY), operating income of JPY 9,500 million (up 16.9% YoY), ordinary income of JPY 11,000 million (up 36.3% YoY), and net income attributable to owners of parent of JPY 8,400 million (up 47.8% YoY), with no revisions made.","jir_financial_highlights":"Net Sales: JPY 87,487 million (Up 8.4% YoY)\nOperating Income: JPY 7,526 million (Up 3.9% YoY)\nOrdinary Income: JPY 8,346 million (Up 9.2% YoY)\nNet Income Attributable to Owners of Parent (Quarterly): JPY 6,342 million (Up 13.2% YoY)\nTotal Assets: JPY 182,220 million (Increase from the previous consolidated fiscal year-end)\nNet Assets: JPY 137,431 million (Increase from the previous consolidated fiscal year-end)\nEquity Ratio: 75.4% (Decreased from 81.6% YoY)\nResearch & Development Expenses: JPY 8,984 million (Unknown)\nNumber of Issued Shares (Common Stock): 36,390,000 shares (Same as YoY)\nNumber of Treasury Shares: 940,091 shares (Almost the same as 939,531 shares YoY)\nAnnual Dividend (Forecast): JPY 80.00 (Same as the previous period)\nFull-year Earnings Guidance Net Sales: JPY 115,500 million (Up 9.8% YoY)\nFull-year Earnings Guidance Operating Income: JPY 9,500 million (Up 16.9% YoY)\nFull-year Earnings Guidance Ordinary Income: JPY 11,000 million (Up 36.3% YoY)\nFull-year Earnings Guidance Net Income Attributable to Owners of Parent: JPY 8,400 million (Up 47.8% YoY)","jir_category":"","jir_hashtags":"#MochidaPharmaceuticalCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 87,487 million (Up 8.4% YoY)\nOperating Income: JPY 7,526 million (Up 3.9% YoY)\nNet Income Attributable to Owners of Parent (Quarterly): JPY 6,342 million (Up 13.2% YoY)","jir_meta_title":"Mochida Pharmaceutical Q3 FY2026 Financial Results: Net Sales of JPY 87,487 Million, Up 8.4% YoY","jir_meta_description":"Mochida Pharmaceutical Co., Ltd.'s financial summary for Q3 FY2026 reports net sales of JPY 87,487 million (up 8.4% YoY), operating income of JPY 7,526 million (up 3.9% YoY), and net income of JPY 6,342 million (up 13.2% YoY). No changes made to the full-year earnings guidance.","jir_og_title":"Mochida Pharmaceutical Q3 FY2026 Financial Summary Released","jir_og_description":"Mochida Pharmaceutical Co., Ltd. announces Q3 FY2026 financial summary with increases in net sales and profits compared to the previous year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[80731,87487],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[7243,7526],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent (Quarterly) Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[5605,6342],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Business Segment Revenue Composition (Q3 FY2026)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical-related Business\\\",\\\"Healthcare Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[81533,5953],\\\"backgroundColor\\\":[\\\"#76b7b2\\\",\\\"#59a14f\\\"]}]}}\"}, {\"jir_chart_id\": \"major_products_sales_growth\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Major Products Sales Growth Rate YoY (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Ryalda\\\",\\\"Goofis\\\",\\\"Movicol\\\",\\\"Toreprost\\\",\\\"Ulys\\\",\\\"Epadel\\\",\\\"Collectment\\\",\\\"Heparin Na\\\",\\\"Generic Drugs\\\",\\\"Dienogest Preparations\\\",\\\"Skincare Products\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"YoY Growth Rate (%)\\\",\\\"data\\\":[9,8,11,46,37,-13,28,4,13,16,8],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-37784","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n